Circulation · 2015 · 124 citations · 47 references
Life SciencesEndocrinologyPhysiologyMetabolic PhysiologyMetabolic RegulationNutritional PhysiologyEndothelial DysfunctionLipid MetabolismLipoprotein MetabolismObesity ManagementWeight LossWeight ManagementBody Weight RegulationEndothelial Activation MarkersEndothelial Function ModulationEndothelial Nitric Oxide Synthase DysfunctionHigh-density Lipoprotein MetabolismLipid Metabolism EffectsNitric OxideVascular Endothelial Dysfunction
BACKGROUND: Roux-en-Y gastric bypass (RYGB) reduces body weight and cardiovascular mortality in morbidly obese patients. Glucagon-like peptide-1 (GLP-1) seems to mediate the metabolic benefits of RYGB partly in a weight loss-independent manner. The present study investigated in rats and patients whether obesity-induced endothelial and high-density lipoprotein (HDL) dysfunction is rapidly improved after RYGB via a GLP-1-dependent mechanism. METHODS AND RESULTS: Eight days after RYGB in diet-induced obese rats, higher plasma levels of bile acids and GLP-1 were associated with improved endothelium-dependent relaxation compared with sham-operated controls fed ad libitum and sham-operated rats that were weight matched to those undergoing RYGB. Compared with the sham-operated rats, RYGB improved nitric oxide (NO) bioavailability resulting from higher endothelial Akt/NO synthase activation, reduced c-Jun amino terminal kinase phosphorylation, and decreased oxidative stress. The protective effects of RYGB were prevented by the GLP-1 receptor antagonist exendin9-39 (10 μg·kg(-1)·h(-1)). Furthermore, in patients and rats, RYGB rapidly reversed HDL dysfunction and restored the endothelium-protective properties of the lipoprotein, including endothelial NO synthase activation, NO production, and anti-inflammatory, antiapoptotic, and antioxidant effects. Finally, RYGB restored HDL-mediated cholesterol efflux capacity. To demonstrate the role of increased GLP-1 signaling, sham-operated control rats were treated for 8 days with the GLP-1 analog liraglutide (0.2 mg/kg twice daily), which restored NO bioavailability and improved endothelium-dependent relaxations and HDL endothelium-protective properties, mimicking the effects of RYGB. CONCLUSIONS: RYGB rapidly reverses obesity-induced endothelial dysfunction and restores the endothelium-protective properties of HDL via a GLP-1-mediated mechanism. The present translational findings in rats and patients unmask novel, weight-independent mechanisms of cardiovascular protection in morbid obesity.
47
A central role for JNK in obesity and insulin resistance
Jiro Hirosumi, Gürol Tuncman, Lufen Chang et al. · Nature · 2002 · 3.3K citations
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Geltrude Mingrone, Simona Panunzi, Andrea De Gaetano et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text
Medicine, Endocrinology, Surgery +16
Kiwon Ban, M. Hossein Noyan-Ashraf, Judith Hoefer et al. · Circulation · 2008 · 1K citations
Medicine, Cardiology, Pharmacology +17
Thomas A. Wadden, Priscilla Hollander, Samuel Klein et al. · International Journal of Obesity · 2013 · 820 citations